4936-47-4
Chemical Structure
Nifuratel
Synonym(s): NF 113; SAP 113; Methylmercadone
- CAS No.: 4936-47-4
- Formula:C10H11N3O5S
- Molecular Weight:285.28
IUPAC Name: (E)-5-((methylthio)methyl)-3-(((5-nitrofuran-2-yl)methylene)amino)oxazolidin-2-one
InChIKey: SRQKTCXJCCHINN-NYYWCZLTSA-N
SMILES: O=C1OC(CSC)CN1/N=C/C2=CC=C([N+]([O-])=O)O2
Biological Activity: Nifuratel (NF 113) is an orally active broad-spectrum antibiotic with antiprotozoal, antibacterial, anticancer and anti-inflammatory activities, and has good inhibitory effects on Candida and Trichomonas. Nifuratel is also a STAT3 inhibitor, which significantly inhibits the growth and proliferation of human gastric cancer cells and induces apoptosis. In addition, Nifuratel also inhibits mast cell-mediated antigen hypersensitivity reactions and can be used in the study of IgE-mediated allergic diseases[1][2][3][4][5][6][7][8].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nifuratel | 99.93% | Nifuratel (NF 113) is an orally active broad-spectrum antibiotic with antiprotozoal, antibacterial, anticancer and anti-inflammatory activities, and has good inhibitory effects on Candida and Trichomonas. Nifuratel is also a STAT3 inhibitor, which significantly inhibits the growth and proliferation of human gastric cancer cells and induces apoptosis. In addition, Nifuratel also inhibits mast cell-mediated antigen hypersensitivity reactions and can be used in the study of IgE-mediated allergic diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nifuratel (Standard) | ≥98% | Nifuratel (Standard) is the analytical standard of Nifuratel. This product is intended for research and analytical applications. Nifuratel (NF 113, SAP 113) is a broad-spectrum antibiotic with activity against bacteria, fungi and trichomonas. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Polatti F. Bacterial vaginosis, Atopobium vaginae and nifuratel. Curr Clin Pharmacol. 2012 Feb 1;7(1):36-40. [Content Brief]
- [2]. Nijevitch AA, et al. Helicobacter pylori eradication in childhood after failure of initial treatment: advantage of quadruple therapy withnifuratel to furazolidone. Aliment Pharmacol Ther. 2005 Nov 1;22(9):881-7. [Content Brief]
- [3]. Nijevitch AA, et al. Nifuratel-containing initial anti-Helicobacter pylori triple therapy in children. Helicobacter. 2007 Apr;12(2):132-5. [Content Brief]
- [4]. Xie T, et al. Nifuratel reduces Salmonella survival in macrophages by extracellular and intracellular antibacterial activity[J]. Microbiology Spectrum, 2023, 11(5): e05147-22. [Content Brief]
- [5]. Zheng H, et al. Nifuratel, a novel STAT3 inhibitor with potent activity against human gastric cancer cells[J]. Cancer management and research, 2017: 565-572. [Content Brief]
- [6]. Lee J E, et al. Drug repositioning of anti-microbial agent nifuratel to treat mast cell-mediated allergic responses[J]. International Journal of Immunopathology and Pharmacology, 2023, 37: 03946320231202349. [Content Brief]
- [7]. Mendling W, et al. Microbiological and pharmaco-toxicological profile of nifuratel and its favourable risk/benefit ratio for the treatment of vulvo-vaginal infections[J]. Arzneimittelforschung, 2002, 52(01): 8-13. [Content Brief]
- [8]. Tynan A P, et al. Nifuratel in urinary infections[J]. British Journal of Urology, 1969, 41(3): 271-279. [Content Brief]
